TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Exelixis Inc (EXEL)

Healthcare Biotechnology
53.00 $
-5.3% vs. previous close
Closing price · As of: 31. Jul 2026

Exelixis Inc (EXEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Revenue" came in at 611 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Income Statement EXEL
Tick rows to compare them in a chart (up to 4) Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 LTM
470 472 480 425 637 540 567 555 568 598 599 611 2,375
18 19 22 21 18 17 20 19 19 19 26 20 84
452 453 458 404 620 522 547 536 549 579 572 591 2,291
233 333 245 228 211 223 249 212 200 199 213 200 813
142 138 91 114 132 112 91 137 135 124 71 140 469
374 471 376 375 344 386 384 349 335 343 337 340 1,354
78 -18 82 29 276 136 163 187 214 237 235 251 937
26
100 5.8 103 49 293 155 185 206 230 252 253 268 1,003
19 4.8 18 12 67 37 45 46 46 59 8.2 57 170
81 1.0 86 37 226 118 140 160 185 194 245 210 833
106 12 110 69 284 195 171 213 238 260 243 275 1,015

LTM = last twelve months (sum of the four most recent quarters).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?